Paper Contents
Abstract
Alopecia areata (AA) is a common autoimmune disorder characterized by unpredictable, non-scarring hair loss, which significantly impacts the quality of life of affected individuals. Current treatments for AA, including corticosteroids and immunosuppressants, have limited efficacy and often carry significant side effects. Deuruxolitinib, a selective Janus kinase (JAK) inhibitor targeting JAK1 and JAK2, has emerged as a promising therapeutic option due to its ability to modulate the immune response implicated in the pathogenesis of AA. This review provides a comprehensive overview of deuruxolitinib, discussing its pharmacological properties, mechanism of action, and clinical efficacy as demonstrated in recent trials. We also explore the safety profile and potential adverse effects associated with deuruxolitinib, comparing it with other JAK inhibitors and highlighting its advantages. Additionally, the paper addresses the future directions for research and clinical application, including the potential for deuruxolitinib to treat other dermatological conditions beyond alopecia areata. By summarizing the current evidence, this review aims to clarify the role of deuruxolitinib in the management of alopecia areata and its potential to improve patient outcomes.Keywords: Alopecia areata, Deuruxolitinib,Hairloss,Infections.
Copyright
Copyright © 2024 Shreesh Tiwari. This is an open access article distributed under the Creative Commons Attribution License.
